Member Info for Hurst10

Simply a case of understanding how a stock like Avacta will behave, post raise and pre news flow and conferences taking place.
We have high profile investors like Susquehanna committing £55mill and with their following , would expect several well known funds joining them.
Elliott group could be one of them , they recently took a 3% stake in Fresenius and are active healthcare investors.

Several conferences happening this week and momentum is picking up and news flow imminent.
130-5 by US hours, anyone selling the next two weeks are making a big mistake.
Making new year high tomorrow.

With Medica on the Diagnostic business and Stifel and Jeffries healthcare conferences in NY and London this week on the Oncology side and with our new US shareholders ( Convertible) on board, plenty of reasons why we will see additional buying interest state side.

Jefferies healthcare conference 15-17/11

With Elliott Management normally following Susquehanna and having recently taken a +3% in Fresenius AG, would not be surprise to see Elliott popping up on the shareholder list of Avacta!

More on the fast growing Stem Cell market:
Repairing tissues and organs makes up a key goal of medicine, and many companies pursue this objective. By 2030, the regenerative-medicine market is projected to reach nearly $38 billion, based on an annual growth rate of more than 15% a year. Much of that growth comes from advances in stem cells and pathways around them.

Last hour, we have +130/ vs 2 x 10 Sales( MM)?
BEGO not moving

With our good friends from Susquehanna on board, holding the convertible, you tend to have Elliott Management right behind!

Nice 50/ buy orders going through the market.

What you have to understand, it is highly unlikely, virtually impossible, that the company would have their US fund committing themselves to the convertible without proper DD and hence comfortable with the progress of AVA6000 etc.
Patience is what is required and off course the company is also attending a leading Diagnostic conference shortly and we have a major conference in the US as well. News flow over the next couple of weeks will be worth waiting for.
The whole AVA portfolio is due a significant re rating which alone will move the share price into new highs !!!!

More potential M&A in the Biotech sector: Horizon Therapeutics, may be a target of an activist after a 13-F filing.
Shows you the the IPO and M&A activity continues to accelerate.
The whole biotech sector is being revalued and with Avacta being a U.K. based predominately USD earner and with an outstanding pipeline, world class science and a differentiated approach, will be an unstoppable engine, growing at outstanding pace.

In the headline of session VI : Non-Radioligand Therapeutics : Pre-clinical development AVA6000, described as a FAP targeted chemotherapeutic agents in Phase 1.So it begs the question : Pre-clinical or Phase 1?

Charts analysis does not apply to Stocks like Avacta.
We have news flow, events etc that will move the share price limit up!!

Proper volume today, conference day, post placing allocation and buyers stepping up a gear pre NY.
We will have buyers paying 45 before lunchtime, enjoy!

Very interesting interesting to hear what C Klein from Roche, who is presenting after F. , have to say.

51/ bought at 130

Watch out for the other side of the two sales prints earlier 131,164 x2

I am pleased to you chaps have picked up what Thermo F is up to and what they are paying for it.
M&A in the sector continues.
JNJ today and IPO’s continues!
Current share prise is a joke, however for the ones who can actually afford to buy shares, it simply does not matter what the share price is at these levels, very soon you will not be able to buy any shares below £4-5.
Do your homework and you will have the Avacta revalued at prices not seen yet.
Diagnostics is taking off as well
Fiona this week end will move the share into new range
Roche is on her panel.
The open offer will have a 100% premium next week.
Good luck everybody, just stay on board!

No interview on Monday.
Focus on Fiona!

If you can, just quietly pick up stock during the day, average price most likely to be 135!!
The key issue is, Avacta needs more shareholders who can actually afford to buy the the shares!